Introduction: Seborrheic keratosis-like lesion of the cervix and vagina is a rare lesion and shows similar morphology to vulvar seborrheic keratosis; 3 of the 7 previously reported cases were associated with low-risk human papillomavirus (HPV) type 42. We report a case of seborrheic keratosis-like lesion of the cervix and provide the first description of the cytological features of this lesion. Case Presentation: A woman in her late forties presented with postcoital bleeding. She had a cervical screening test following which she underwent cervical biopsy, endocervical and endometrial curettage, large loop excision of the transformation zone of the cervix, and hysterectomy. Results: The liquid-based cytology preparation showed cohesive groups of mildly atypical squamoid cells with a spindle cell morphology, mildly increased nuclear to cytoplasmic ratio, prominent nucleoli, and occasional nuclear grooves. No koilocytes were identified. Molecular genotyping revealed positivity for HPV type 42. Discussion/Conclusion: This represents the first description of the cytological features of a seborrheic keratosis-like lesion of the cervix, which are distinctive and unusual. Whilst the mild squamous atypia raised the possibility of a low-grade squamous intraepithelial lesion, no koilocytes were identified. The association in our case with a low-risk HPV type, HPV 42, provides further evidence for a role of this HPV type in the pathogenesis of these lesions.

1.
AbdullGaffar
B
,
Keloth
TR
,
Raman
LG
,
Mahmood
S
,
Almulla
A
,
AlMarzouqi
M
,
Unusual benign polypoid and papular neoplasms and tumor-like lesions of the vulva
.
Ann Diagn Pathol
.
2014
;
18
(
2
):
63
70
. .
2.
Talia
KL
,
McCluggage
WG
.
Seborrheic keratosis-like lesions of the cervix and vagina: report of a new entity possibly related to low-risk human papillomavirus infection
.
Am J Surg Pathol
.
2017
;
41
(
4
):
517
24
. .
3.
Anderson L, Saville M, Wright G; Cancer Council Australia Cervical Cancer Screening Guidelines 223 Working Party. In: Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National cervical screening program: guidelines for the management of screen- detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Sydney: Cancer Council Australia. [Version URL: https://wiki.cancer.org.au/australiawiki/index.php?oldid=190192; cited 224 2021 Jan 6]. Available from: https://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening/Cytology_and_AMBS_2004_terminology_for_reporting Available from: https://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening.
4.
Cancer Council Australia Cervical Cancer Screening Guidelines Working Party
.
National cervical screening program: guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding
.
Sydney
:
Cancer Council Australia
. [Version URL: https://wiki.cancer.org.au/australiawiki/index.php?oldid=214337; cited 2021 Jan 18]. Available from: https://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening.
5.
Bai
H
,
Cviko
A
,
Granter
S
,
Yuan
L
,
Betensky
RA
,
Crum
CP
.
Immunophenotypic and viral (human papillomavirus) correlates of vulvar seborrheic keratosis
.
Hum Pathol
.
2003
;
34
(
6
):
559
64
. .
6.
Reutter
JC
,
Geisinger
KR
,
Laudadio
J
.
Vulvar seborrheic keratosis: is there a relationship to human papillomavirus?
J Low Genit Tract Dis
.
2014
;
18
(
2
):
190
4
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.